Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €266.78 EUR
Change Today -3.95 / -1.46%
Volume 7.4K
As of 1:37 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

roche holding ag-genusschein (RHO5) Snapshot

Open
€269.33
Previous Close
€270.73
Day High
€271.00
Day Low
€266.40
52 Week High
04/22/15 - €274.25
52 Week Low
05/7/14 - €205.54
Market Cap
229.2B
Average Volume 10 Days
9.7K
EPS TTM
--
Shares Outstanding
702.6M
EX-Date
03/5/15
P/E TM
--
Dividend
€7.73
Dividend Yield
2.80%
Current Stock Chart for ROCHE HOLDING AG-GENUSSCHEIN (RHO5)

roche holding ag-genusschein (RHO5) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Europe, North America, and Asia. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, drug metabolism disorder, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, human papillomavirus, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and west nile virus diseases. The company also provides diagnostic solutions for blood gas analysis; blood screening; cancer screening; cardiac markers; cardiovascular testing; cholesterol monitoring; coagulation monitoring, routing, and specialty testing; data management; diabetes monitoring and therapy; electrolytes analysis; emergency medicine; hemostasis; heterogeneous immunochemistry; homogenous immune assays; immunology; infectious diseases; intensive care testing; microarray; neonatal intensive care units; nucleic acid purification; PCR clinical diagnostics; pharmacogenomics; physical fitness and platelet function testing; PCR diagnostic systems; serum work area; urinalysis; and workflow solutions. In addition, it offers products for researchers, such as amplification, cell analysis, gene expression, gene knockdown, genome sequencing, microarrays, nucleic acid purification, protein analysis, PCR systems, and transfection products. The company has collaboration agreements with AmorChem, AbbVie, Xenon Pharmaceuticals, Stratos Genomics, The Garvan Institute, Cornell University, and University of Washington. The company was founded in 1896 and is headquartered in Basel, Switzerland.

88,509 Employees
Last Reported Date: 01/28/15
Founded in 1896

roche holding ag-genusschein (RHO5) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.3M
Chief Financial Officer and IT Officer
Total Annual Compensation: SFr.4.1M
Chief Operating Officer of Pharmaceuticals di...
Total Annual Compensation: SFr.5.0M
Chief Operating Officer of Diagnostics Divisi...
Total Annual Compensation: SFr.2.5M
General Counsel and Corporate Secretary
Total Annual Compensation: SFr.2.8M
Compensation as of Fiscal Year 2014.

roche holding ag-genusschein (RHO5) Key Developments

Roche Reports Sales Results for the First Quarter of 2015; Provides Sales Guidance for the Year 2015

Roche reported sales results for the first quarter of 2015. For the quarter, the company reported 3% rise in sales despite a strong Swiss franc. Sales rose to CHF 11.8 billion from CHF 11.4 billion last year. For the year 2015, the company continues to expect sales to grow low- to mid-single digit, at constant exchange rates.

ROG Seeks Acquisitions

Roche Holding AG (SWX:ROG) is seeking acquisitions. Roche Chief Executive Officer remains interested in acquiring products and technologies, but not a mega merger.

Inovio Pharmaceuticals and Roche Initiate Clinical Trial for Inovio's DNA Immunotherapy to Treat Chronic Hepatitis B Infection

Inovio Pharmaceuticals, Inc. announced that it has initiated a phase I trial to evaluate Inovio's DNA immunotherapy in patients who are chronically infected with hepatitis B. In 2013, Roche and Inovio entered into a partnership to co-develop and commercialize Inovio's hepatitis B immunotherapy. This trial initiation triggers a $3 million milestone payment from Roche to Inovio. This phase I, randomized, open-label, active-controlled, dose escalation study will evaluate the safety, tolerability, and immunogenicity of Inovio's hepatitis B immunotherapy, INO-1800, alone or in combination with INO-9112, Inovio's IL-12-based immune activator. This international study will enroll patients in the United States and Asia Pacific region with a primary endpoint of safety and tolerability of the therapy. The secondary endpoints will evaluate the cellular and humoral immune response to INO-1800 and investigate the therapy's effect on several viral and antiviral parameters. All trial subjects are also medicated with standard-of-care antiviral therapies. Inovio has reported preclinical data showing its hepatitis B immunotherapy (INO-1800) generated strong T-cell and antibody responses that led to the elimination of targeted liver cells in mice. These results indicate that the immunotherapy may have potential in the treatment of hepatitis B infection. In a preclinical study, researchers found hepatitis B-specific T-cells exhibited a killing function, and could migrate to and stay in the liver and cause clearance of target cells without evidence of liver injury. This was the first study to provide evidence that intramuscular immunization can induce killer T-cells that can migrate to the liver and eliminate target cells.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHO5:GR €266.78 EUR -3.95

RHO5 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €135.20 EUR +0.435
Gilead Sciences Inc $103.70 USD -1.51
Novartis AG SFr.99.80 CHF -0.80
Pfizer Inc $35.27 USD -0.09
Sanofi €95.86 EUR +0.51
View Industry Companies
 

Industry Analysis

RHO5

Industry Average

Valuation RHO5 Industry Range
Price/Earnings 26.2x
Price/Sales 4.8x
Price/Book 12.3x
Price/Cash Flow 21.3x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-GENUSSCHEIN, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.